Subscribe

TTP or MAHA | Bevacizumab (Avastin, Anti-VEGF) Therapy Side Effects

Purpose:

To identify thrombotic thrombocytopenic purpura (TTP) or microangiopathic hemolytic anemia in a patient treated with Avastin.

Specialty:

Hematology Oncology

Objective:

adverse effects

ICD-10:

M31.1, T45.1

Description:

Bevacizumab (Avastin) is an antibody that targets vascular endothelial growth factor (VEGF). It may be effective against a number of solid tumors, but it is also associated with a number of serious toxicities, one of which is a hemolytic anemia.

To read more or access our algorithms and calculators, please log in or register.

RECENT TWEETS

medal descover
medal iphone